查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
肝癌诊断市场规模、份额和趋势分析报告：按测试类型（实验室测试、成像、内窥镜检查、活检）、最终用途、地区、细分市场预测 2023-2030 年
市场调查报告书
商品编码
1178637

肝癌诊断市场规模、份额和趋势分析报告：按测试类型（实验室测试、成像、内窥镜检查、活检）、最终用途、地区、细分市场预测 2023-2030 年

Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

肝癌诊断市场的增长和趋势

根据 Grand View Research, Inc. 的最新报告，全球肝癌诊断市场规模在 2023 年至 2030 年的预测期内将以 6.67% 的复合年增长率增长，到 2030 年将达到 146.7 亿美元。据报导预计将达到肝癌患病率的增加、诊断技术的进步以及对筛查治疗和生存重要性的认识正在推动肝癌诊断市场的增长。

根据美国癌症协会的统计数据，预计 2022 年将诊断出约 41,260 例肝癌新病例。2020年，Globocan宣布全球约有830,180人死于肝癌。世卫组织还估计，慢性肝炎病毒感染在人群中很普遍，丙型肝炎病毒 (HCV) 影响了大约 5800 万人。HCV 和乙型肝炎病毒 (HBV) 是肝癌最常见的相关危险因素。此外，肝硬化和吸烟等其他危险因素的流行增加了对早期治疗和诊断肝癌以提高生存率的筛查解决方案的需求。因此，在预测期内对诊断的需求将上升，推动市场增长。

COVID-19 大流行扰乱了肝癌患者的治疗并导致高死亡率。筛查和治疗的延误和中断影响了该病患者。例如，在 2021 年 6 月的一篇论文中，来自欧洲国家的研究人员评估了大流行对肝癌患者常规护理的影响，并得出结论认为修正案显着改变了结果。然而，在 COVID-19 期间技术的进步和对免疫系统的了解导致许多新的医疗保健诊断产品的推出。此外，大流行病提高了健康的重要性，定期进行健康检查以早期诊断和治疗已渗透到人群中。

世界各地许多公共和私营组织的提高认识和宣传工作推动了诊断技术的进步。因此，有望为增加筛查和诊断各种癌症创造环境，促进诊断解决方案的发展。例如，2022 年 9 月，总部位于美国的诊断公司 Delfi Diagnostics, Inc. 宣布已被选为欧洲大规模筛查试验的液体活检合作伙伴。

一些公司正在推出新产品，以满足对肝癌早期检测创新解决方案日益增长的需求。例如，2020 年 3 月，F. Hoffmann-La Roche（以下简称 F.Roche）以新的 Elecsys GALAD 评分获得了美国 FDA 的“突破性设备指定”。该评分通过为临床医生提供及时准确的信息来支持肝细胞癌 (HCC) 的诊断。大公司也在为新产品开发寻求联合研究、协议和伙伴关係。此类产品的开发和推出将加剧市场竞争，刺激肝癌诊断市场的增长。

肝癌诊断市场亮点

按测试类型划分，由于对准确且具有成本效益的疾病阶段诊断的需求不断增长，实验室测试将在 2022 年占据最大份额。此外，用于监测对治疗方案的反应的实验室测试的应用也推动了增长。

按最终用途划分，医院和诊断实验室部分在 2022 年主导了市场。在医疗专业人员的帮助下，对这些环境作为初级保健中心进行诊断和治疗的偏好正在推动这一领域的增长。

由于人口中普遍存在风险因素，北美将在 2022 年占据最高份额。这是由于该地区对疾病筛查的认识不断提高，以及越来越多地采用先进技术，这推动了增长。

由于疾病流行和大量老年人口的存在，预计亚太地区在 2023 年至 2030 年的预测期内将出现最快的增长。新兴经济体还将推动该地区新兴经济体采用诊断测试。

目录

第一章 调查方法和范围

  • 调查方法
  • 调查假设
  • 信息采购
    • 购买的数据库
    • GVR内部数据库
    • 次要信息
    • 初步调查
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证

第二章执行摘要

  • 市场快照
  • 段快照
  • 竞争格局的快照

3. 市场变量、趋势和范围

  • 母市场分析
  • 市场动态
    • 市场驱动力分析
      • 肝癌患病率增加
      • 公共和私人机构举措的增加
      • 肝癌危险因素的患病率增加
      • 技术进步
    • 市场约束因素分析
      • 影像诊断费用高
      • 辐射暴露可能会限制 Ct 的使用
  • 绘製渗透率和增长前景
  • 肝癌诊断市场-波特分析
  • 肝癌诊断市场-SWOT 分析
  • COVID-19 影响分析

第四章检验类业务分析

  • 肝癌诊断市场-测试类型的变化分析
  • 临床检查
    • 生物标誌物
      • 癌胚抗原和糖蛋白抗原
      • □和同工□
      • 生长因子和受体
      • 分子标记
      • 病理生物标誌物
    • 验血
  • 成像
  • 内窥镜检查
  • 活检
  • 其他

第 5 章最终用途业务分析

  • 肝癌诊断市场-最终用途趋势分析
  • 医院和诊断实验室
  • 学术/研究机构
  • 製药和氯实验室

第六章区域业务分析

  • 肝癌诊断市场：区域趋势分析
  • 北美
    • SWOT分析
    • 美国
      • 主要国家动态
      • 竞争情景
      • 美国肝癌诊断市场，2018-2030（百万美元）
  • 欧洲
    • SWOT分析
    • 英国
      • 主要国家动态
      • 竞争情景
      • 英国肝癌诊断市场，2018-2030（百万美元）
    • 德国
      • 主要国家动态
      • 竞争情景
      • 德国肝癌诊断市场，2018-2030（百万美元）
    • 法国
      • 主要国家动态
      • 竞争情景
      • 法国肝癌诊断市场，2018-2030（百万美元）
    • 意大利
      • 主要国家动态
      • 竞争情景
      • 意大利肝癌诊断市场，2018-2030（百万美元）
    • 西班牙
      • 主要国家动态
      • 竞争情景
      • 西班牙肝癌诊断市场，2018-2030（百万美元）
    • 丹麦
      • 主要国家动态
      • 竞争情景
      • 丹麦肝癌诊断市场，2018-2030（百万美元）
    • 瑞典
      • 主要国家动态
      • 竞争情景
      • 瑞典肝癌诊断市场，2018-2030（百万美元）
    • 挪威
      • 主要国家动态
      • 竞争情景
      • 挪威肝癌诊断市场，2018-2030（百万美元）
    • 欧洲其他地区
      • 主要国家动态
      • 竞争情景
      • 其他欧洲肝癌诊断市场，2018-2030（百万美元）
  • 亚太地区
    • SWOT分析
    • 日本
      • 主要国家动态
      • 竞争情景
      • 日本肝癌诊断市场，2018-2030（百万美元）
    • 中国
      • 主要国家动态
      • 竞争情景
      • 中国肝癌诊断市场，2018-2030（百万美元）
    • 印度
      • 主要国家动态
      • 竞争情景
      • 印度肝癌诊断市场，2018-2030（百万美元）
    • 韩国
      • 主要国家动态
      • 竞争情景
      • 韩国肝癌诊断市场，2018-2030（百万美元）
    • 澳大利亚
      • 主要国家动态
      • 竞争情景
      • 澳大利亚肝癌诊断市场，2018-2030（百万美元）
    • 泰国
      • 主要国家动态
      • 竞争情景
      • 泰国肝癌诊断市场，2018-2030（百万美元）
    • 亚太其他地区
      • 主要国家动态
      • 竞争情景
      • 亚太地区其他肝癌诊断市场，2018-2030（百万美元）
  • 拉丁美洲
    • SWOT分析
    • 巴西
      • 主要国家动态
      • 竞争情景
      • 巴西肝癌诊断市场，2018-2030（百万美元）
    • 墨西哥
      • 主要国家动态
      • 竞争情景
      • 墨西哥肝癌诊断市场，2018-2030（百万美元）
    • 阿根廷
      • 主要国家动态
      • 竞争情景
      • 阿根廷肝癌诊断市场，2018-2030（百万美元）
    • 其他拉丁美洲
      • 主要国家动态
      • 竞争情景
      • 拉丁美洲其他地区肝癌诊断市场，2018-2030（百万美元）
  • 中东和非洲（Mea）
    • SWOT分析
    • 南非
      • 主要国家动态
      • 竞争情景
      • 南非肝癌诊断市场，2018-2030（百万美元）
    • 阿拉伯联合酋长国
      • 主要国家动态
      • 竞争情景
      • 阿拉伯联合酋长国肝癌诊断市场，2018-2030（百万美元）
    • 科威特
      • 主要国家动态
      • 竞争情景
      • 科威特肝癌诊断市场，2018-2030（百万美元）
    • 其他中东/非洲
      • 主要国家动态
      • 竞争情景
      • 中东和非洲其他地区肝癌诊断市场，2018-2030（百万美元）

第七章竞争格局

  • 参赛者概览
    • Abbott Laboratories
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Qiagen N.V.
    • Seimens Healthineers
    • Becton, Dickinson & Company
    • Fujifilm Medical Systems U.S.A., Inc.
    • Illumina, Inc.
    • Epigenomics Ag
    • Koninklijke Philips N.V.
  • 财务绩效
  • 进入公司
    • 市场领导者
      • 2022 年肝癌诊断市场份额分析
    • 战略规划
      • 扩张
      • 获得
      • 合作
      • 产品/服务发布
      • 合伙
      • 其他
Product Code: GVR-3-68038-012-5

Liver Cancer Diagnostics Market Growth & Trends:

The global liver cancer diagnostics market size is expected to reach USD 14.67 billion by 2030, advancing at a CAGR of 6.67% over the forecast period from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of liver cancer, the technological advancements for diagnosis, and the awareness of screening importance for treatment & survival rate are driving the market growth for liver cancer diagnostics.

According to the American Society of Cancer statistics in 2022, around 41,260 new cases are expected to be diagnosed with liver cancer. It was also presented by Globocan in 2020, that about 830,180 deaths were accounted by liver cancer worldwide. WHO also estimates that chronic hepatitis viral infections are widespread in the population, with hepatitis C virus (HCV) affecting about 58 million people. HCV and hepatitis B virus (HBV) are the most commonly associated risk factors of liver cancer. In addition, the infection prevalence and exposure to other risk factors such as cirrhosis and smoking will upsurge the demand for screening solutions for early treatment & diagnosis of liver cancer to increase the survival rate. Thus, the demand for diagnostics products will boost during the forecast period, thereby driving market growth.

The COVID-19 pandemic disrupted liver cancer patient care and resulted in higher mortality rates. The delayed or interrupted screening & procedures impacted the patients with the disease. For example, in a June 2021 article, researchers from European countries assessed the pandemic's impact on routine care of liver cancer patients and concluded that the modifications significantly altered the outcomes. However, with advancements in technology and a better understanding of the immune system during COVID-19, many new healthcare diagnostic products have been launched. Moreover, the pandemic boosted the importance of health and pushed the population toward regular health screening for early diagnosis & treatment.

The technological advancement in diagnosis has resulted from increased awareness and supportive initiatives by many public-private organizations worldwide. This will result in a conducive environment to increase the screening as well as diagnosis of various cancers and is expected to propel the growth of diagnostics solutions. For example, in September 2022, Delfi Diagnostics, Inc., a U.S.-based diagnostics company, announced that it has been selected as the liquid biopsy partner in a large-scale screening trial in Europe.

To cater to the increased demand for innovative solutions for the early detection of liver cancer, multiple companies are launching new products. For instance, in March 2020, F. Hoffmann-La Roche Ltd. Roche received the 'Breakthrough Device Designation' from the US FDA for its new Elecsys GALAD score. The score supports clinicians in the diagnosis of hepatocellular carcinoma (HCC) by providing them with timely and accurate information. Key companies are also undergoing collaborations, agreements, and partnerships for new product developments. Such product developments & launches will intensify the market competition and fuel the market growth for liver cancer diagnostics.

Liver Cancer Diagnostics Market Report Highlights:

  • On basis of test type, laboratory tests held the largest share in 2022, owing to the increased demand for accurate & cost-effective diagnosis of disease stages. In addition, the application of laboratory tests for monitoring response to treatment plans also propels the growth
  • Based on end-use, the hospitals and diagnostic laboratories segment dominated the market in 2022. The preference for these settings as primary care centers for the diagnosis and treatment with the help of medical professionals boosts the segment's growth
  • North America accounted for the highest share in 2022 due to the prevalence of risk factors in the population. This has resulted from the increased awareness about disease screening and the growing adoption of advanced technologies in this region, driving the growth
  • Asia Pacific will exhibit the fastest growth during the forecast period of 2023-2030, owing to the prevalence of diseases and the presence of a large geriatric population in the region. In addition, the developing economies will boost the adoption of diagnostic tests in the region's emerging countries

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Research Methodology
  • 1.2 Research Assumptions
    • 1.2.1 Estimates And Forecast Timeline
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Landscape Snapshot

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Parent Market Analysis
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increasing Prevalence Of Liver Cancer
      • 3.2.1.2 Rising Initiatives Undertaken By Public And Private Organizations
      • 3.2.1.3 Increasing Prevalence Of Risk Factors For Liver Cancer
      • 3.2.1.4 Technological Advancements
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 High Cost Of Diagnostic Imaging
      • 3.2.2.2 Radiation Exposure Likely To Limit Usage Of Ct
  • 3.3 Penetration & Growth Prospect Mapping
  • 3.4 Liver Cancer Diagonstics Market - Porter's Analysis
  • 3.5 Liver Cancer Diagonstics Market - Swot Analysis
  • 3.6 Covid-19 Impact Analysis

Chapter 4 Test Type Business Analysis

  • 4.1 Liver Cancer Diagonstics Market - Test Type Movement Analysis
  • 4.2 Laboratory Tests
    • 4.2.1 Global Laboratory Tests Market, 2018 - 2030 (USD Million)
    • 4.2.2 Biomarkers
      • 4.2.2.1 Global Biomarkers Market, 2018 - 2030 (USD Million)
      • 4.2.2.2 Oncofetal And Glycoprotein Antigens
      • 4.2.2.2.1 Global Oncofetal And Glycoprotein Antigens Market, 2018 - 2030 (USD Million)
      • 4.2.2.3 Enzymes And Isoenzymes
      • 4.2.2.3.1 Global Enzymes And Isoenzymes Market, 2018 - 2030 (USD Million)
      • 4.2.2.4 Growth Factors And Receptors
      • 4.2.2.4.1 Global Growth Factors And Receptors Market, 2018 - 2030 (USD Million)
      • 4.2.2.5 Molecular Markers
      • 4.2.2.5.1 Global Molecular Markers Market, 2018 - 2030 (USD Million)
      • 4.2.2.6 Pathological Biomarkers
      • 4.2.2.6.1 Global Pathological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.2.3 Blood Tests
      • 4.2.3.1 Global Bloos Tests Market, 2018 - 2030 (USD Million)
  • 4.3 Imaging
    • 4.3.1 Global Imaging Market, 2018 - 2030 (USD Million)
  • 4.4 Endoscopy
    • 4.4.1 Global Endoscopy Market, 2018 - 2030 (USD Million)
  • 4.5 Biopsy
    • 4.5.1 Global Biopsy Market, 2018 - 2030 (USD Million)
  • 4.6 Others
    • 4.6.1 Global Other Tests Type Market, 2018 - 2030 (USD Million)

Chapter 5 End-Use Business Analysis

  • 5.1 Liver Cancer Diagonstics Market-End Use Movement Analysis
  • 5.2 Hospitals & Diagnostic Laboratories
    • 5.2.1 Global Hospitals & Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
  • 5.3 Academic & Research Institutes
    • 5.3.1 Global Academic & Research Institutes Market, 2018 - 2030 (USD Million)
  • 5.4 Pharmaceutical & Cro Laboratories
    • 5.4.1 Global Pharmaceutical & Cro Laboratories Market, 2018 - 2030 (USD Million)

Chaper 6 Regional Business Analysis

  • 6.1 Liver Cancer Diagonstics Market: Regional Movement Analysis
  • 6.2 North America
    • 6.2.1 Swot Analysis
      • 6.2.1.1 North America Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 Key Country Dynamics
      • 6.2.2.2 Competitive Scenario
      • 6.2.2.3 U.S. Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.2.3 Rest Of Europe
      • 6.2.3.1 Key Country Dynamics
      • 6.2.3.2 Competitive Scenario
      • 6.2.3.3 Rest Of Europe Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
  • 6.3 Europe
    • 6.3.1 Swot Analysis
      • 6.3.1.1 Europe Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.3.2 U.K.
      • 6.3.2.1 Key Country Dynamics
      • 6.3.2.2 Competitive Scenario
      • 6.3.2.3 U.K. Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.3 Germany
      • 6.3.3.1 Key Country Dynamics
      • 6.3.3.2 Competitive Scenario
      • 6.3.3.3 Germany Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.4 France
      • 6.3.4.1 Key Country Dynamics
      • 6.3.4.2 Competitive Scenario
      • 6.3.4.3 France Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.5 Italy
      • 6.3.5.1 Key Country Dynamics
      • 6.3.5.2 Competitive Scenario
      • 6.3.5.3 Italy Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.6 Spain
      • 6.3.6.1 Key Country Dynamics
      • 6.3.6.2 Competitive Scenario
      • 6.3.6.3 Spain Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.7 Denmark
      • 6.3.7.1 Key Country Dynamics
      • 6.3.7.2 Competitive Scenario
      • 6.3.7.3 Denmark Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.8 Sweden
      • 6.3.8.1 Key Country Dynamics
      • 6.3.8.2 Competitive Scenario
      • 6.3.8.3 Sweden Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.9 Norway
      • 6.3.9.1 Key Country Dynamics
      • 6.3.9.2 Competitive Scenario
      • 6.3.9.3 Norway Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.3.10 Rest Of Europe
      • 6.3.10.1 Key Country Dynamics
      • 6.3.10.2 Competitive Scenario
      • 6.3.10.3 Rest Of Europe Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Swot Analysis
      • 6.4.1.1 Asia Pacific Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.4.2 Japan
      • 6.4.2.1 Key Country Dynamics
      • 6.4.2.2 Competitive Scenario
      • 6.4.2.3 Japan Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.4.3 China
      • 6.4.3.1 Key Country Dynamics
      • 6.4.3.2 Competitive Scenario
      • 6.4.3.3 China Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.4.4 India
      • 6.4.4.1 Key Country Dynamics
      • 6.4.4.2 Competitive Scenario
      • 6.4.4.3 India Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.4.5 South Korea
      • 6.4.5.1 Key Country Dynamics
      • 6.4.5.2 Competitive Scenario
      • 6.4.5.3 South Korea Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.4.6 Australia
      • 6.4.6.1 Key Country Dynamics
      • 6.4.6.2 Competitive Scenario
      • 6.4.6.3 Australia Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.4.7 Thailand
      • 6.4.7.1 Key Country Dynamics
      • 6.4.7.2 Competitive Scenario
      • 6.4.7.3 Thailand Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.4.8 Rest Of Asia Pacific
      • 6.4.8.1 Key Country Dynamics
      • 6.4.8.2 Competitive Scenario
      • 6.4.8.3 Rest Of Apac Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Swot Analysis
      • 6.5.1.1 Latin America Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Key Country Dynamics
      • 6.5.2.2 Competitive Scenario
      • 6.5.2.3 Brazil Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.5.3 Mexico
      • 6.5.3.1 Key Country Dynamics
      • 6.5.3.2 Competitive Scenario
      • 6.5.3.3 Mexico Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.5.4 Argentina
      • 6.5.4.1 Key Country Dynamics
      • 6.5.4.2 Competitive Scenario
      • 6.5.4.3 Argentina Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.5.5 Rest Of Latin America
      • 6.5.5.1 Key Country Dynamics
      • 6.5.5.2 Competitive Scenario
      • 6.5.5.3 Rest Of Latam Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
  • 6.6 Middle East & Africa (Mea)
    • 6.6.1 Swot Analysis
      • 6.6.1.1 Mea Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 Key Country Dynamics
      • 6.6.2.2 Competitive Scenario
      • 6.6.2.3 South Africa Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.6.3 Rest Of Middle East & Africa
      • 6.6.3.1 Key Country Dynamics
      • 6.6.3.2 Competitive Scenario
      • 6.6.3.3 Rest Of Middle East & Africa Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.6.4 Uae
      • 6.6.4.1 Key Country Dynamics
      • 6.6.4.2 Competitive Scenario
      • 6.6.4.3 Uae Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.6.5 Kuwait
      • 6.6.5.1 Key Country Dynamics
      • 6.6.5.2 Competitive Scenario
      • 6.6.5.3 Kuwait Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
    • 6.6.6 Rest Of Mea
      • 6.6.6.1 Key Country Dynamics
      • 6.6.6.2 Competitive Scenario
      • 6.6.6.3 Rest Of Mea Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 7 Competitive Landscape

  • 7.1 Participant's Overview
    • 7.1.1 Abbott Laboratories
    • 7.1.2 Thermo Fisher Scientific, Inc.
    • 7.1.3 F. Hoffmann-La Roche Ltd.
    • 7.1.4 Qiagen N.V.
    • 7.1.5 Seimens Healthineers
    • 7.1.6 Becton, Dickinson & Company
    • 7.1.7 Fujifilm Medical Systems U.S.A., Inc.
    • 7.1.8 Illumina, Inc.
    • 7.1.9 Epigenomics Ag
    • 7.1.10 Koninklijke Philips N.V.
  • 7.2 Financial Performance
  • 7.3 Participant Categorization
    • 7.3.1 Market Leaders
      • 7.3.1.1 Liver Cancer Diagnostics Market Share Analysis, 2022
    • 7.3.2 Strategy Mapping
      • 7.3.2.1 Expansion
      • 7.3.2.2 Acquisition
      • 7.3.2.3 Collaborations
      • 7.3.2.4 Product/Service Launch
      • 7.3.2.5 Partnerships
      • 7.3.2.6 Others

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 Global liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 Global liver cancer diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 6 North America liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 8 North America liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 9 U.S. liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 10 U.S. liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 11 Rest of Europe liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 12 Rest of Europe liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 13 Europe liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 14 Europe liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 15 Europe liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 16 U.K. liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 17 U.K. liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 Germany liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 19 Germany liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 France liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 21 France liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 22 Italy liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 23 Italy liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Spain liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 25 Spain liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Denmark liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 27 Denmark liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 28 Sweden liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 29 Sweden liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 30 Norway liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 31 Norway liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 Japan liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 36 Japan liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 37 China liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 38 China liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 India liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 40 India liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 South Korea liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 42 South Korea liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 43 Australia liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 44 Australia liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 45 Thailand liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 46 Thailand liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 Latin America liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 48 Latin America liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 49 Latin America liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 Brazil liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 51 Brazil liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 52 Mexico liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 53 Mexico liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 54 Argentina liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 55 Argentina liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa liver cancer diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 South Africa liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 60 South Africa liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 Rest of Middle East & Africa liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 62 Rest of Middle East & Africa liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 63 UAE liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 64 UAE liver cancer diagnostics market, by end-use, 2018 - 2030 (USD Million)
  • Table 65 Kuwait liver cancer diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 66 Kuwait liver cancer diagnostics, by end-use, 2018 - 2030 (USD Million)
  • Table 67 Participant's overview
  • Table 68 Financial performance
  • Table 69 Key companies undergoing expansions
  • Table 70 Key companies undertaking acquisitions
  • Table 71 Key companies undergoing collaborations
  • Table 72 Key companies launching new products/services
  • Table 73 Key companies undergoing partnerships
  • Table 74 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market summary, 2022 (USD Million)
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Market driver impact
  • Fig. 11 Market restraint impact
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Porter's analysis
  • Fig. 14 SWOT analysis
  • Fig. 15 Liver cancer diagnostics market: Test type outlook and key takeaways
  • Fig. 16 Liver cancer diagnostics market: Test type movement analysis
  • Fig. 17 Global oncofetal and glycoprotein antigens market, 2018 - 2030 (USD Million)
  • Fig. 18 Global enzymes and isoenzymes market, 2018 - 2030 (USD Million)
  • Fig. 19 Global growth factors and receptors market, 2018 - 2030 (USD Million)
  • Fig. 20 Global molecular markers readers market, 2018 - 2030 (USD Million)
  • Fig. 21 Global pathological biomarkers market, 2018 - 2030 (USD Million)
  • Fig. 22 Global blood tests market, 2018 - 2030 (USD Million)
  • Fig. 23 Global imaging market, 2018 - 2030 (USD Million)
  • Fig. 24 Global endoscopy market, 2018 - 2030 (USD Million)
  • Fig. 25 Global biopsy market, 2018 - 2030 (USD Million)
  • Fig. 26 Global other tests type market, 2018 - 2030 (USD Million)
  • Fig. 27 Liver cancer diagnostics market: End-use outlook and key takeaways
  • Fig. 28 Liver cancer diagnostics market: End-use movement analysis
  • Fig. 29 Global hospitals & diagnostic laboratories market, 2018 - 2030 (USD Million)
  • Fig. 30 Global academic & research institutes market, 2018 - 2030 (USD Million)
  • Fig. 31 Global pharmaceutical & CRO laboratories market, 2018 - 2030 (USD Million)
  • Fig. 32 Liver cancer diagnostics market: Regional outlook and key takeaways
  • Fig. 33 North America: SWOT Analysis
  • Fig. 34 North America liver cancer diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 35 US key country dynamics
  • Fig. 36 US liver cancer diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 37 Rest of Europe key country dynamics
  • Fig. 38 Rest of Europe liver cancer diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 39 Europe: SWOT Analysis
  • Fig. 40 Europe liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 UK key country dynamics
  • Fig. 42 UK liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Germany key country dynamics
  • Fig. 44 Germany liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 France key country dynamics
  • Fig. 46 France liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Italy key country dynamics
  • Fig. 48 Italy liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Spain key country dynamics
  • Fig. 50 Spain liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark key country dynamics
  • Fig. 52 Denmark liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden key country dynamics
  • Fig. 54 Sweden liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Norway key country dynamics
  • Fig. 56 Norway liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Rest of Europe key country dynamics
  • Fig. 58 Rest of Europe liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Asia-Pacific: SWOT Analysis
  • Fig. 60 Asia-Pacific liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Japan key country dynamics
  • Fig. 62 Japan liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 China key country dynamics
  • Fig. 64 China liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 India key country dynamics
  • Fig. 66 India liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea key country dynamics
  • Fig. 68 South Korea liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Australia key country dynamics
  • Fig. 70 Australia liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 Thailand key country dynamics
  • Fig. 72 Thailand liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Rest of Asia Pacific key country dynamics
  • Fig. 74 Rest of Asia Pacific liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Latin America: SWOT Analysis
  • Fig. 76 Latin America liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 Brazil key country dynamics
  • Fig. 78 Brazil liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Mexico key country dynamics
  • Fig. 80 Mexico liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina key country dynamics
  • Fig. 82 Argentina liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Rest of Latin America key country dynamics
  • Fig. 84 Rest of Latin America liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Middle East & Africa: SWOT Analysis
  • Fig. 86 Middle East & Africa liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 87 South Africa key country dynamics
  • Fig. 88 South Africa liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 89 Rest of Middle East & Africa key country dynamics
  • Fig. 90 Rest of Middle East & Africa liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 91 UAE key country dynamics
  • Fig. 92 UAE liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 93 Kuwait key country dynamics
  • Fig. 94 Kuwait liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 95 Rest of Middle East & Africa key country dynamics
  • Fig. 96 Rest of Middle East & Africa liver cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 97 Heat map analysis
  • Fig. 98 Market participant categorization
  • Fig. 99 Liver cancer diagnostics market share analysis, 2022
  • Fig. 100 Strategy framework